Article Text

PDF
Disease progression and liver cancer in the ferroportin disease
  1. Elena Corradini1,
  2. Francesca Ferrara1,
  3. Teresa Pollicino2,
  4. Alberto Vegetti3,
  5. Gian Luca Abbati3,
  6. Luisa Losi4,
  7. Giovanni Raimondo5,
  8. Antonello Pietrangelo6
  1. 1Department of Internal Medicine, Center for Hemochromatosis, University Hospital of Modena, Modena, Italy
  2. 2Department of Internal Medicine, Unit of Clinical and Molecular Hepatology, University Hospital of Messina, Messina, Italy
  3. 3Department of Internal Medicine, Center for Hemochromatosis, University Hospital of Modena, Modena, Italy
  4. 4Department of Anatomy and Pathology, University Hospital of Modena, Modena, Italy
  5. 5Department of Internal Medicine, Unit of Clinical and Molecular Hepatology, University Hospital of Messina, Messina, Italy
  6. 6Department of Internal Medicine, Center for Hemochromatosis, University Hospital of Modena, Modena, Italy
  1. Correspondence to:
    Professor A Pietrangelo
    Department of Internal Medicine, Center for Hemochromatosis, Policlinico, Via del Pozzo 71 41100 Modena, Italy; pietrangelo.antonello{at}unimo.it

Statistics from Altmetric.com

Ferroportin-associated iron overload (also known as the ferroportin disease) was clinically recognised in 1999,1 and linked in 2001 to the A77D mutation of ferroportin (FPN).2 Owing to the mild clinical expressivity reported in the literature, doubts have been raised on the penetrance of the genetic defect and the rationale for iron-removal therapy.3 However, so far, no prospective data have been collected pertaining to this disorder.

We have had the opportunity to study six members of a pedigree carrying the A77D mutation of FPN for 11–24 years in whom the disease was first described.1,2

The proband (subject V13, table 1) was diagnosed at the age 59 years. After being on weekly phlebotomy for 2 years, he was on a maintenance programme for 18 years (one phlebotomy every 3 months). At the age of 79 years, he refused to continue on phlebotomy. In 2006, at the …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.